Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Decline; Fiscal 2025 Outlook Trimmed

MT Newswires Live

2025/10/30

Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 128 Japanese yen ($0.83) per share, down from 134 yen a year earlier.

Two analysts polled by FactSet expected 66.98 yen.

Revenue for the quarter ended Sept. 30 was 1.113 trillion yen, compared with 1.176 trillion yen a year earlier.

Analysts polled by FactSet expected 1.197 trillion yen

The company said it now expects fiscal 2025 core earnings of 479 yen per share, from 485 yen previously. Analysts polled by FactSet expect 246.9 yen.

Takeda also lowered its fiscal 2025 revenue guidance to 4.5 trillion yen, from 4.53 trillion yen previously. Analysts polled by FactSet expect 4.582 trillion yen.

Shares of Takeda Pharmaceutical were down nearly 2% in recent premarket activity Thursday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579111892"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579111892\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579111892?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 17:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579111892","market":"sg","top_or_hot":-1,"title":"Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Decline; Fiscal 2025 Outlook Trimmed","media":"MT Newswires Live","content":"<html><body><p> Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 128 Japanese yen ($0.83) per share, down from 134 yen a year earlier.</p><p>Two analysts polled by FactSet expected 66.98 yen.</p><p>Revenue for the quarter ended Sept. 30 was 1.113 trillion yen, compared with 1.176 trillion yen a year earlier.</p><p>Analysts polled by FactSet expected 1.197 trillion yen</p><p>The company said it now expects fiscal 2025 core earnings of 479 yen per share, from 485 yen previously. Analysts polled by FactSet expect 246.9 yen.</p><p>Takeda also lowered its fiscal 2025 revenue guidance to 4.5 trillion yen, from 4.53 trillion yen previously. Analysts polled by FactSet expect 4.582 trillion yen.</p><p>Shares of Takeda Pharmaceutical were down nearly 2% in recent premarket activity Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Decline; Fiscal 2025 Outlook Trimmed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Decline; Fiscal 2025 Outlook Trimmed\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-30 17:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 128 Japanese yen ($0.83) per share, down from 134 yen a year earlier.</p><p>Two analysts polled by FactSet expected 66.98 yen.</p><p>Revenue for the quarter ended Sept. 30 was 1.113 trillion yen, compared with 1.176 trillion yen a year earlier.</p><p>Analysts polled by FactSet expected 1.197 trillion yen</p><p>The company said it now expects fiscal 2025 core earnings of 479 yen per share, from 485 yen previously. Analysts polled by FactSet expect 246.9 yen.</p><p>Takeda also lowered its fiscal 2025 revenue guidance to 4.5 trillion yen, from 4.53 trillion yen previously. Analysts polled by FactSet expect 4.582 trillion yen.</p><p>Shares of Takeda Pharmaceutical were down nearly 2% in recent premarket activity Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2579111892","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579111892","pubTimestamp":1761816763,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takeda Pharmaceutical  reported fiscal Q2 core earnings Thursday of 128 Japanese yen  per share, down from 134 yen a year earlier.Two analysts polled by FactSet expected 66.98 yen.Revenue for the quarter ended Sept. 30 was 1.113 trillion yen, compared with 1.176 trillion yen a year earlier.Analysts polled by FactSet expected 1.197 trillion yenThe company said it now expects fiscal 2025 core earnings of 479 yen per share, from 485 yen previously. Analysts polled by FactSet expect 246.9 yen.Takeda also lowered its fiscal 2025 revenue guidance to 4.5 trillion yen, from 4.53 trillion yen previously. Analysts polled by FactSet expect 4.582 trillion yen.Shares of Takeda Pharmaceutical were down nearly 2% in recent premarket activity Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","BK4007":"制药"},"translate_title":"武田制药第二财季核心盈利、营收下降；2025财年前景下调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1},"content_text":"Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 128 Japanese yen ($0.83) per share, down from 134 yen a year earlier.Two analysts polled by FactSet expected 66.98 yen.Revenue for the quarter ended Sept. 30 was 1.113 trillion yen, compared with 1.176 trillion yen a year earlier.Analysts polled by FactSet expected 1.197 trillion yenThe company said it now expects fiscal 2025 core earnings of 479 yen per share, from 485 yen previously. Analysts polled by FactSet expect 246.9 yen.Takeda also lowered its fiscal 2025 revenue guidance to 4.5 trillion yen, from 4.53 trillion yen previously. Analysts polled by FactSet expect 4.582 trillion yen.Shares of Takeda Pharmaceutical were down nearly 2% in recent premarket activity Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}